(NASDAQ: TMDX) Transmedics Group's forecast annual revenue growth rate of 20.37% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.53%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.77%.
Transmedics Group's revenue in 2026 is $566,354,000.On average, 16 Wall Street analysts forecast TMDX's revenue for 2026 to be $25,236,713,783, with the lowest TMDX revenue forecast at $23,001,371,185, and the highest TMDX revenue forecast at $27,052,395,670. On average, 14 Wall Street analysts forecast TMDX's revenue for 2027 to be $29,683,135,209, with the lowest TMDX revenue forecast at $26,457,762,415, and the highest TMDX revenue forecast at $32,524,388,589.
In 2028, TMDX is forecast to generate $33,545,517,420 in revenue, with the lowest revenue forecast at $30,891,881,084 and the highest revenue forecast at $35,267,903,400.